Evidence map›Paper›PMID 38187373›Full record

ReviewFrontiers in immunology2023

m

Chen Peng, Fen Xiong, Xi Pu, Zhangmin Hu, Yufei Yang, Xuehan Qiao, Yuchun Jiang, Miao Han, Deqiang Wang, Xiaoqin Li

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Epitranscriptomics Regulation of CD70, CD80, and TIGIT in Cancer Immunity.International journal of molecular sciences · 2025
    Article
  5. Article
  6. m6A: a novel strategy for osteoporosis treatment.Frontiers in cell and developmental biology · 2025
    Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Chen Peng *Department of Medical Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Fen Xiong *Department of Medical Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Xi Pu *Department of Gastroenterology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Zhangmin HuDepartment of Medical Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Yufei YangDepartment of Medical Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Xuehan QiaoDepartment of Medical Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Yuchun JiangDepartment of Medical Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Miao HanDepartment of Medical Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Deqiang WangInstitute of Digestive Diseases, Jiangsu University, Zhenjiang, China.
Xiaoqin LiDepartment of Medical Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Affiliated Hospital of Jiangsu University · CNJiangsu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

N

Indexed as

Gastrointestinal NeoplasmsCatalytic DomainHumansImmune Checkpoint InhibitorsImmunotherapyMethylationMethyltransferasesTumor MicroenvironmentImmune Checkpoint InhibitorsMethyltransferasesMETTL3 protein, humancatalytic subunit m 6 A-METTL complexgastrointestinal cancersimmune cell infiltrationimmunotherapyMETTL3/14N 6 -methyladenosine (m 6 A) methylation modification

Identifiers

PMID38187373
PMCPMC10768557
OpenAlexW4389794004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.